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TOPOGRAPHY STUDY OF FIXA: GENERATION OF A LIPID 
ANCHORED MOLECULAR RULER WITH ATTACHED INHIBITOR 
 
 
Abstract 
 
Blood coagulation, an important hemostatic property, is directed through 
activation of proteolytic enzymes known as serine proteases to generate a fibrin 
plug. Using multiple proteases allows for localized and precise regulation of 
blood coagulation within the circulatory system.  Factor IX, a serine protease, is a 
key activator in the coagulation cascade by activating Factor X.  For activation of 
FX to occur, FIXa must be in proper conformation on the platelet surface with 
cofactor FVIIIa to increase enzymatic abilities of FIXa a billion-fold.  Current 
research looks at structure and function of FIXa yet neglects structural plasticity 
on the membrane, with function of FIX clearly being related to conformation on 
the platelet.  The role of this investigation was to study the optimal reactive 
topography of FIXa by generating AMRI, Adjustable height Molecular Ruler with 
attached Inhibitor. AMRI composed of three primary regions contains an Anchor 
region, Linker region, and Inhibitor.  AMRI was generated using the protein 
anchoring sequence LAGC to fixate to a lipid surface.  A height adjustable linker 
area was then required between the anchor and inhibitor regions of AMRI to 
ensure proper vertical height of inhibitor.  The linker sequence EAAAK forms a 
rigid structure with a vertical height of 7.5A above the membrane surface, thus 
we repeated this sequence to achieve a specific desired height. Completing the 
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protein’s linker region is a flexible linker at end of the rigid set. That flexible linker 
ensures the inhibitor will fit in FIXa active site. Finishing the AMRI complex is a 
PN2-KPI inhibitor, which has been demonstrated to fit and inhibit the catalytic site 
of FIXa.  Therefore, AMRI should allow for determination of optimal reactive 
height of the FIXa active site without affecting structural conformation.  Through 
the generation of AMRI, a greater insight into blood coagulation will be gained, 
along with potential for site specific anticoagulant clinical applications. 
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1 Background and Significance 
1.1 Hemostasis 	
Humans are dependent upon the circulation of blood through a pressurized vascular 
network to sustain life.  Continuous blood flow is vital for the transport of nutrients, 
hormones, and waste to allow proper cellular function.  The body includes five major 
vessel types christened arteries, arterioles, capillaries, venules, and veins.  The arteries 
and veins contain three different layers termed the tunica intima, tunica media, and 
tunica adventitia; constructing the inner, middle, and outer layers, respectively.  The 
arterioles and venules contain two layers, tunica intima, and tunica media.  The 
capillaries contain only one layer, the tunica intima.  The tunica intima is composed of a 
single layer of endothelial cells found in all blood vessels.  The other two layers of the 
blood vessels are comprised of an extracellular matrix composed of collagens, elastins, 
fibrils, and proteoglycans, which provide structure and regulation to blood flow(1,	2).  
Hemostasis is the balance of clotting at the site of injury, fibrinolysis as part of 
healing and preventing the random clotting to allow flow of blood throughout its system.  
The hemostatic system has the responsibility of maintaining integrity of the closed 
vascular system.  Vascular integrity can be affected by a multitude of things including, a 
needle used to draw someone’s blood, rupture of an atherosclerotic plaque, or a deep 
laceration during a motor vehicle accident.  It is possible that one of these events or 
others could affect an individual at any given time, significantly affecting blood flow.  
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Failure of vascular integrity resulting in diminished hemostasis will lead to various clinical 
pathologies and in extreme circumstances, tissue, and cellular death(3).  
 	
1.2 Platelet Activation and Coagulation Cascade 	
The process of blood changing from a flowing liquid to forming a solid clot is 
coagulation.  The ultimate goal of coagulation is to achieve hemostasis, by pinpointing 
and obstructing the loss of blood at the site of vascular injury.  This happens with the 
activation and adhesion of platelets providing a surface for clotting enzymes to undergo 
a series of reactions forming a clot.  These series of enzymatic reactions in conjunction 
with platelets can seal off the area of vascular damage by generation of a non-soluble 
plasma protein, fibrin(4-6) . 
Platelets are found in significant numbers within the blood.  In intact blood circulation, 
platelets are smooth, discoid in shape, and contain an internal canalicular system.  
Additionally, platelets contain granules containing von Willebrand Factor (vWF), platelet-
activating factor, and other platelet activating materials(7,	8) . 
Activation of platelets is initiated by a rupture in the vessel endothelial lining, 
exposing von Willebrand Factor (vWF) and extracellular matrix proteins, such as 
collagen, to the blood.  This contact between surface receptors on the platelet with these 
proteins causes the conformational changes in platelets by extending their pseudopodia 
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contained within the canalicular system (8).  Translocation of the pseudopodia exposes 
the anionic phospholipid layer on their outer surface for attachment of other platelets, 
vWF, and other proteins(8-10) .  
The mechanism behind the translocation is caused by a platelet membrane receptor, 
GPIa, which induces the platelet conformational change (see Figure 1).  This change 
exposes a second platelet membrane receptor GPIb and in the presence of vWF, 
induces greater conformational change.  This greater change exposes the GPIIb/GPIII 
receptor proteins, allowing for binding of more collagen and vWF(8).  
Once platelets are activated, these platelets begin to adhere to one another, in a 
process called platelet adhesion.  Just as the activation cause the extension of the 
pseudopodia and adhesion, it causes the granules to be released from the canalicular 
system as well.  By releasing the granules, this creates more soluble vWF to activate 
more platelets (8) . 
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Now with activated platelets, this self-sealing system employs the combination of the 
tissue factor pathway and the 
contact activation pathway; 
termed extrinsic and intrinsic 
pathways, respectively.  These 
pathways are a series of 
sequential reactions, in which 
the inactive enzyme precursors 
(zymogens) of a serine protease 
activates to become an activated 
serine protease.  The 
coagulation cascade zymogens are called Factors and identified by Roman numerals 
(see Table 1 for a list).  Once the Factor has been activated its name indicates so by 
following the name with the letter “a”; i.e. Factor IX (FIX) activated is Factor IXa (FIXa).  
That serine protease plants on the phospholipid surface provided by the platelet, thus 
catalyzing the next reaction in the cascade by cleaving the downstream substrate.  The 
intrinsic and extrinsic cascades work in tandem having the goal of activating Factor X 
(FX), prothrombin (FII), and cleaving fibrinogen (FI) (11-15) . 
  
	
Figure	1.	Plate	Adhesion	Steps	Figure	1.	Platelet	Adhesion	Steps.	GpIa	binds	the	exposed	subendothelial	collagen	(Step	1)	and	allows	GpIb	to	bind	vWF	(Step	2).	This	binding	with	vWF	exposes	the	(Step	3)	GpIIb-GpIIIa	complex.	This	image	was	adapted	from:	Lieberman	M,	Marks	AD.	Marks'	basic	medical	biochemistry	
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Table 1 Blood Coagulation Proteins. 
Common Name Alternative Descriptive Name Function/Active Form 
FI Fibrinogen Fibrin 
FII* Prothrombin Serine protease 
FIII Tissue Factor(TF) Receptor, Cofactor, and Initiator 
FIV Ca2+ Cofactor 
FV Proaccelerin, labile factor Cofactor 
FVII* Proconvertin Serine protease 
FVIII Antihemophilia factor A Cofactor for FIX activation 
FIX* Antihemophilia factor B, Christmas factor Serine protease 
FX* Stuart-Prower factor Serine protease 
FXI 
Plasma 
thromboplastin 
antecedent 
Serine protease 
FXII Hageman Factor Serine Protease 
FXIII Fibrin-stabilizing factor Ca
2+-dependent transglutaminase 
Thrombomodulin  Thrombin Cofactor in Protein C Activation, Endothelial Cell Receptor 
Protein C*  Serine Protease, Activated by Thrombomodulin-bound thrombin 
Protein S*  Cofactor for activated Protein C 
Antithrombin III ATIII Protease Inhibitor 
Blood	Coagulation	Proteins	with	Common	Name,	Descriptive	Name,	and	Function.		An	activated	form	has	an	“a”	added	to	the	common	name.		An	*	indicated	the	proteins	that	are	Vitamin	K	dependent.			
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The Extrinsic pathway, as seen in figure 2,  is composed of Tissue Factor (TF) and 
Factor VII (FVII) to activate FX (16) .  TF is expressed on subendothelial tissues and 
fibroblast cells outside of the vasculature.  This is vital for pinpoint identification of a 
vascular break and formation of the TF-FVIIa complex (3,	17,	18) .  The TF-FVIIa 
complex then activates FX and FIX (19,	20). 
The Intrinsic pathway is composed Coagulation Factors IX, VIII, and XI (see Figure 
2). Again, the goal is to activate Factor X and ultimately generate a thrombin burst.  The 
pathway starts with the activation of FXII that converts FXI to FXIa.  FXIa then cleaves 
FIX, activating to create FIXa.  Then FIXa interacts with FVIIIa to form the tenase 
complex, whose role is to activate FX into FXa (12).  
 
Extrinsic and 
intrinsic pathway 
activation results in 
the activation of the 
common pathway for 
a favorable thrombin 
generation state (see 
Figure 2).  The 
central objective of 
the common pathway 
is to activate FX, 
	
Figure	2.		Blood	Coagulation	Cascade	showing	the	overall	goal	of	activation	of	FX	to	Xa	to	for	the	prothrombin	complex	to	form	a	hard	fibrin	clot.	Not	shown	are	the	necessary	cofactors	that	are	required	for	full	procoagulant	activity.	Adapted	from:	Lieberman	M,	Marks	AD.	Marks'	basic	medical	biochemistry:	A	clinical	approach.	4th	ed.	Lippincott	Williams	&	Wilkins;	2012. 
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thrombin, and fibrin, inducing clotting.  This central objective is best achieved when 
coagulation is viewed as the Cell-Based Model for Coagulation (CBMC) (21).  The 
CBMC model accounts for the fact that both pathways are necessary to form a fibrin clot 
and that if one is deficient this leads to clinical issues such as hemophilia or 
spontaneous clot formation.  CBMC is a four-step process for coagulation, composed of 
Initiation, Amplification, Propagation, and Termination (21). 
Initiation occurs when trauma leads to the exposure of TF, extracellular collagen, and 
von Willebrand Factor (vWF) (13,	17,	22).  These indicators allow for injury site detection 
with pinpoint precision and initiate a response.  Platelets, activated by vWF and 
extracellular collagen, extend their pseudopodia.  The activation of platelets and 
exposure of the TF bearing tissue to circulating blood is important for providing an 
anionic phospholipid layer for the coagulation factors to sit on (12,	23). 
Simultaneous to the platelet activation is the formation of a complex between 
Coagulation Factor VII (FVII) and Tissue Factor (TF) (23).  FVII activation is brought 
about by auto-activation or activation by trace amounts of FXa (24).   Formation of this 
complex activates a small amount of FIX and FX via proteolytic cleavage, producing 
FIXa and FXa (10,	25,	26).  This small amount of FXa will activate a small amount of 
thrombin needed to allow for progression to amplification. 
Amplification started with the initiation step providing the necessary materials of 
activated FIX, FX, and importantly thrombin.  The small amount of thrombin generated 
during initiation activates FV, FVIII, and FXI.  FXIa is a potent activator of FIX, and FVa 
is an important cofactor for FXa (27,	28).  FVIIIa is an important cofactor for FIXa and 
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thrombin spurs its release from vWF to bind with FIXa.  With these cofactor and factors 
activated, it amplifies the quantity of pro-coagulation complexes to proceed into the 
propagation phase (11,	29).  
Propagation is a fully primed intrinsic/extrinsic response to generate fibrin.  On the 
platelet surface the tenase (Xase) complex of FVIIIa and FIXa activates FX to FXa.  FXa 
then forms the prothrombinase assembly with FVa to convert prothrombin to thrombin (8).  This functional prothrombinase assembly generates the thrombin burst.  This 
thrombin burst catalyzes the cleavage of fibrinogen into fibrin thus forming the clot at the 
area of injury.  The insoluble fibrin monomers aggregate together to form a soft clot.  
Activation of FXIII to FXIIIa (Transglutaminase) then crosslinks the fibrin clots.  This 
cross-linking forms a rigid network trapping the platelets and erythrocytes inside, forming 
the hard clot. 
Termination, the fourth step of CBMC, is continually ongoing as it employs multiple 
routes to keep the other three coagulation steps in check.  This process ensures healthy 
vasculature does not form random clots and dissolves the clots that have formed.  
Formation of spontaneous clots could lead to clinical issues such as thrombus and 
ultimately result in an embolism (21).  
To accomplish this never-ending task, termination employs the Protein C/Protein S/ 
Thrombomodulin System (21).  Protein C is an anticoagulant zymogen, when bound to 
its cofactor thrombomodulin (TM) (5,	30-33).  TM inhibits the clotting abilities of thrombin 
and activates Protein C.  Activated Protein C binds with cofactor Protein S to form the 
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Protein C-Protein S complex that can terminate thrombin generation on platelets by 
destroying FVa and FVIIIa (34,	35).  
Fibrinolysis, the process of breaking down a formed clot occurs as part of normal 
wound healing.  The primary enzyme that breaks down the fibrin clot is plasmin.  The 
inactive pro-enzyme, plasminogen, flows throughout the blood and activates on contact 
with the clot surface to form plasmin.  Activation occurs by activator proteins called 
tissue plasminogen activator (tPA) and single chain urokinase (scu-PA).  Plasmin begins 
to break down the fibrin resulting in full dissolution of the clot once the wound has fully 
healed. 
1.3 Serine Proteases 
Hemostatic regulation occurs through the employment of coagulation factors known 
as serine proteases. Serine protease production occurs in the liver’s hepatocytes and 
then they circulate as zymogens in the blood.  Proteolytic cleavage turns these inactive 
enzyme precursors into active serine proteases.  Minute differences allow them to 
operate with the high degree of specificity to provide precision with regulation. 
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All serine proteases share a great deal of similarity in gene sequence (29,	36,	37).  
Sharing a high degree of DNA and amino acid similarity, protein folding delivers similar 
structure patterns throughout the serine proteases.  As demonstrated in the general 
clotting factor structure shown in Figure 3.  The 
clotting proteases are composed of a catalytic head, 
two Epidermal Growth Factor (EGF)-like domains, 
and a Gla domain (29,	38,	39).  This can be best 
imagined if thought about as a Venus Flytrap. 
The catalytic head resembles the digestive 
enzyme trypsin and forms the “fly catching portion” 
of the flytrap.  The catalytic head contains the 
protease domain to hydrolyze peptide bonds by 
utilizing a “catalytic triad” of Serine, Histidine, and 
Asparagine (40-43).  This “catalytic triad” is 
responsible for the activation of the next sequential 
protease.   
Holding up the catalytic head like a stem, are the 
two EGF-like domains.  The primary role of EGF-like domains is to hold the catalytic 
head off the phospholipid surface and into the space above (41,	42,	44).  This area also 
contains some binding sites for regulators and co-factors of the enzyme.  A flexible linker 
attached to the two EGF-like domains holds the catalytic head (41,	42).   
	
Figure	3	Structure of coagulation factor. 
The EGF1 and EGF2 domains are the 
“stem” portion holding up the catalytic 
head. The “root” of the structure is the Gla 
domain, that anchors the coagulation 
factor to the phospholipid surface.  
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The Gla domain refers to the conserved feature of amino-terminal carboxylated 
glutamic acid residues that serve to anchor the entire structure (41).  These modified 
residues serve to anchor the entire structure via calcium bridging to the phospholipid 
surface (38,	39,	44).  The interaction of the Gla domain is possible by the Vitamin K 
dependent, γ-carboxylase modification to the glutamate residues during synthesis in 
hepatocytes of the liver (24).  
The γ-carboxylation occurs via a quinone reductase that reduces Vitamin K to KH2. 
Carboxylase enzyme cofactor Vitamin KH2 adds the carboxyl group to the Gla domain.  
Calcium with a positive charge chelates via electrostatic interaction the negative charged 
Gla domain and the anionic head group of phospholipids (25,	41). 
Coagulation factors employ cofactors to assist in the protease activity.  These 
cofactors are comprised of factor specific cofactors in addition to the universal cofactors.  
This relationship allows for pivotal coagulation cascade reactions to occur through 
improved posturing of the factor/substrate orientation. 
Universal Cofactors that are required by all serine proteases in the coagulation 
cascade are calcium and an anionic phospholipid membrane.  Radcliffe et al. found that 
adding phospholipids and CaCl2 caused an 11-fold increase in activation of FVII (22).  
Calcium serving as a cofactor with a positive charge chelates via electrostatic interaction 
the negative charged Gla domain and the anionic head group of phospholipids (25,	41).  
The interaction between the Gla domain and EGF-like domains is also highly dependent 
upon calcium for orientation on the membrane in the vertical position of the serine 
proteases, as described by Bode et al. 1997 (32).  Krishnaswamy et al.  also 
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demonstrated evidence that substrate-membrane interaction considerably enhances 
activation of FX by the extrinsic Xase complex (14,	45,	46).  Without proper vertical 
orientation and attachment to the phospholipid membrane the serine proteases exhibit 
very reduced activity (45). 
Though all serine proteases share a great deal of similarity in DNA and amino acid 
sequence they are highly specific for activation, cofactor, and substrate (29,	36,	37).  
Important cofactor/factor relationships that greatly increase protease activity are: FVIIa 
to TF, FVIIIa to FIXa, and FVa to FXa.  These specific relationships are what give way 
for an optimal Km and Kcat. 
As previously mentioned, the key role of FXa is to activate FII.  FX activates 
prothrombin via two methods and speeds: FXa alone slowly or at exponentially greater 
rate with the cofactors in the prothrombinase complex.  The prothrombinase complex 
forms when there is vascular injury, and the platelet provides a phospholipid surface for 
FXa, with cofactor FVa, acting on the substrate, Prothrombin.  Specifically, FXa performs 
activation of FII via proteolytic cleavage of two peptide bonds on the heavy chain, turning 
FII into FIIa (46).  
To best understand the role of serine proteases and their respective cofactors it is 
important to look at Protein C, a serine protease whose function is to oppose 
coagulation.  Activated Protein C (APC) is crucial to the regulation of the clotting 
cascade by acting on procoagulant serine proteases.  Protein C shares similar structure 
and generation to the Vitamin K dependent, pro-coagulant serine proteases synthesized 
in the liver (30).  APC in complex with cofactor Activated Protein S (APS), forms the 
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APC/APS complex that is responsible for degradation of FVa and FVIIIa.  Protein C is 
activated by thrombin, and this activation is enhanced when thrombin is attached to 
thrombomodulin.  Thrombomodulin is a cofactor for thrombin found on the surface of 
endothelial cells (34,	35).  Walker et al. found that Protein C has a high degree of 
specification and once activated cleaves both chains of the activated clotting enzymes, 
FVa and FVIIIa (14,	30).  Just as with FXa alone can activate a small amount of 
prothrombin, it was identified that Protein C can inactivate FVa and FVIIIa 
independently, but the Km is substantially decreased by the cofactors (30).  Interestingly 
it was discovered that the complex is not able to inactivate FVIIIa when, FVIIIa is 
coupled with cofactor vWF (35). 
FVIIa bound to TF in association with calcium on phospholipid surface forms the 
extrinsic tenase complex and is the preliminary activator of FX (17,	22,	47).  TF presiding 
as the cofactor for FVIIa embraces the protease in optimal vertical orientation off the 
membrane surface (48).  McCallum et al. demonstrated the ability of the cofactor to be 
so necessary for orientation it allows for prime positioning even if the Gla domain of 
FVIIa becomes detached (18,	26,	49). 
Kovalenki et al. investigated the activation of FX to FXa by the extrinsic tenase 
complex and found that the size of the vesicle affected the rate of the reaction (50,	51).  
This is important because it draws attention to the topographical and geometrical limits 
of the factors while sitting vertically on the phospholipid membrane 
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1.4 Factor IX 
Factor IX (FIX) 
shares similar homology 
with other vitamin K 
dependent clotting 
factors produced in the 
liver.  It is an essential 
clotting factor and a 
deficiency in FIX can lead 
to clinical issues such as 
hemophilia B, also known 
as Christmas Disease (52,	53).  Analyzing the 
DNA sequence data of 
the proband patient who 
had a bleeding disorder 
identified the disease as being a unique form of hemophilia.  This mutation resulted in a 
cysteine changed into a serine on the X chromosome within what is now identified as the 
FIX gene (52-55). 
The general structure of FIX shares a similar homology with the other serine 
proteases (see figure 4).  More specifically FIX is composed of two chains equaling 415 
amino acids, a C-terminal heavy and N-terminal light chain (52).  The C-terminal Heavy 
chain of 235 amino acids forms from residues 181 to 415 (44).  The N-terminal light 
	
Figure	4	Structure of Factor IX in Ribbon View with protein structure. 
Photo by Jawahar Swaminathan and MSD staff at the European 
Bioinformatics Institute / Public domain 
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chain consists of 145 amino acids (39).  Together light and heavy chains are linked with 
a disulfide bond at Cys-132 and Cys-189 (40-43). 
This heavy chain contains the FIX catalytic head region as previously described in 
the general description of serine proteases.  The importance of the FIX catalytic head is 
that it specifically contains the “Catalytic Triad” composed of Histidine-236, Serine-365, 
and Asparagine-269 (40-43).  This catalytic triad is responsible for the activation of FX. 
The N-terminal light chain includes the Gla domain and two EGF-like domains (39).  
The Gla domain of FIX is composed of the amino acid residues 1-38, which anchors the 
enzyme with the calcium bridge to the phospholipid membrane of the platelet or other 
phospholipid surface (39,	44).  EGF-like domains are residues 47 to 84 and 85 to 127 (42).  There is also a hydrophobic helix at residues 39 to 46, which acts as a support for 
the EGF-like domains (41).  Both EGF-like domains are stacked and joined with a 
convex hydrophobic loop of EGF1 and a concave hydrophobic socket of EGF2 (41).  A 
flexible linker with residues 128 to 145 holds the catalytic head (41,	42).   
Activation of FIX occurs by the intrinsic and extrinsic pathways.  FXIa is the activator 
in the intrinsic pathway model and FVIIa in the extrinsic pathway.  FIX activation is in two 
cleavage events performed by FVIIa/TF or FXIa (56).  The first cleavage generates 
FIXaα with a single cleavage removing Arg-180 to Val-181, followed by a second 
cleavage removing Ala-146 to Arg-180 to generate FIXaβ (42,	57). 
Fully activated FIXaβ forms the Xase complex, with specific cofactor FVIIIa and 
universal cofactors.  The role of FIX catalytic head is activation of FX by hydrolysis of 
peptide bonds at Arg-194 to Ile-195 (40-43).  This complex has been demonstrated to 
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have 109-fold increase in the procoagulant activity compared to active, non-complexed 
FIXa, as reviewed by Neuenschwander et al. (56,	58).  
The anticipated height of FIXa is a distance between 50 to 100 Å above the 
membrane.  A review and understanding of the FIXa structural dependency on cofactors 
is fundamental.  X-ray crystal structures have demonstrated the ability of cofactors and 
ions to change the conformation of factors in the clotting cascade.  Length changes of 
the serine protease, specifically FIX have been demonstrated with cofactors.  Bode et al. 
and McCallum et al. determined how the interaction between the EGF1 domain and Gla 
domain is highly dependent upon calcium (41,	59).  When there is a lack of calcium the 
protease is no longer able to chelate to the phospholipid surface.  Also, through small 
angle x-ray and NMR studies, a change in orientation based on calcium has been 
detected (41,	44).  The EGF-like domains’ binding sites for cofactor FVIIIa act upon the 
final structure of Xase complex.  When bound, they promote activation of FIX by holding 
in the vertical orientation (41).  While all of these studies point to the orientation of the 
complex, none are capable of addressing the specific optimal distance and orientation of 
the catalytic head with regard to stretch and flexibility of the factor (60). 
1.5 Anti-Coagulation and Inhibitor Structure 
Anticoagulants are chemicals used in the prevention of blood clotting by acting on 
clotting factors within the Coagulation Cascade.  Anticoagulants have a long history of 
uses throughout evolution by animals such as mosquitos to obtain blood from the host 
animal (61).  Currently, anticoagulants are used as therapies in patients, for example 
with atrial fibrillation to prolong an individual’s survival.  Most of the current anticoagulant 
therapies used in medical practice involve coumarins and heparins (62). 
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Looking at the mechanism by which coumarins work it is important to look 
specifically at the drug Warfarin.  Warfarin first used by man as a rat poison was later 
approved for use as an anticoagulant by acting as a Vitamin K analog (63).   Vitamin K 
activity is impeded by Warfarin interacting with Vitamin K epoxide reductase.  Without 
enough active Vitamin K to carboxylate the Gla residues on Vitamin K dependent serine 
proteases they are no longer able to chelate the phospholipid surface (21,	44).  This is a 
common way to prevent blood coagulation but has negatives to its uses such as a drug 
loading time, taking around 72 hours before effects are seen in a patient. 
The polymer, heparin is another common anticoagulant used by medical 
professionals in things such as blood filtration procedures and surgeries.  Heparin is 
naturally produced in the body by basophils and mast cells and can be extracted for 
pharmaceutical uses from mammals such as cattle and pork.  Heparin works by binding 
and increasing activity of Antithrombin III (AT) (15,	32,	61,	64-66). 
Antithrombin (AT) belongs to a class of inhibitors known as serine protease inhibitors 
or serpins.  Serpins contain a serine residue in their catalytic triad to help regulate the 
proteolytic clotting cascade.  A principal class of serpins is Kunitz Protease Inhibitors, 
which includes AT.  AT is a small glycoprotein produced in the liver, which binds to the 
serine residue in the active catalytic triad of thrombin, leaving it inactive.  Other common 
serpins of FXa and FIXa are Basic Pancreatic Trypsin Inhibitor (BPTI) and Protease 
Nexin-2, respectively, via their Kunitz Protease Inhibitor domains (58,	67).  To tie this 
together heparin has also been shown to increase the rate of AT and FIXa inhibition in 
the presence of Ca2+ (58). 
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2 Research Design 
As discussed, blood coagulation requires the use of enzymes orchestrated in a 
series of highly specific events.  For these events to occur at a tremendous exponential 
rate, the enzymes require their respective cofactors and a phospholipid membrane.  It 
has also been determined that the topographical characteristics of the activation 
complex on the phospholipid membrane are also essential.  Fluorescence studies have 
delved into the distance of closest approach to the membrane of the active site for 
several of the coagulation serine proteases (42-44,	49,	59,	60,	68,	69).  In several 
instances, it was documented that the non-enzymatic cofactor binding altered the 
distance.  With distance above the membrane correlated to the overall length of the 
serine protease as determined by x-ray crystal structures, it is reasoned that proteases 
orient vertically on the membrane with little to no bending (Figure 5).  This reasoning has 
not been proven using fluorescence resonance energy transfer (FRET)-based studies as 
these are only capable of showing the distance of closest approach.  FRET cannot 
determine the optimal height/distance needed for maximum coagulation activity.  Also, 
lacking in the gap of knowledge is the potential for elasticity and their ability to stretch off 
the membrane, proving to be a significant gap in knowledge.  The goal of this study to 
gain insight into the optimal reactive height of coagulation factor IXa above the 
phospholipid surface by the generation of a lipid Anchored Molecular Ruler with 
attached Inhibitor (AMRI).  
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The enzymatic 
characterization of 
coagulation factors has 
been frequently studied 
through use of small 
peptide inhibitors such 
as serpins, as they sit 
directly in the catalytic 
site of the enzyme (38,	70-73) .  Hence, we 
are using it in the 
AMRI.  To generate 
AMRI, a protein 
anchoring sequence of 
Leucine, Alanine, 
Glycine, and Cysteine (LAGC) is used to fixate the entire structure to a lipid surface.  To 
direct the lipid-bound protein for anchoring, LAGC will be coupled with a leader 
sequence for shuffling into periplasmic space, originally from the Apyrase gene of 
Shigella, for protein collection.  A height adjustable linker area is then required between 
the anchor and inhibitor regions of AMRI to ensure the proper height of inhibitor.  
Employing the linker sequence EAAAK, with a rigid slantwise fixed height of 7.5 Å per 
sequence, will allow for the creation of a specific height for the engineered protein (74).  
Based on the Crystal structure data the hypothesized reactive height is a distance 
between 50 to 100Å above the membrane (6,	42,	43,	69).  Completing the protein's linker 
	
Figure 5  Demonstration of knowledge lacking in the optimal 
reactive height of FIXa. This looks at Crystal Structure Data (A) 
and FRET (B). The Crystal structure gives us the height at a 
moment frozen in time. FRET data gives  the distant of closest 
approach.  Lacking is the information on the wobble (C) and the 
stretch (D) to understand how the Factor moves in a fluid 
environment for optimal reactivity.  
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region will be a flexible linker at the end of a rigid set to ensure the inhibitor properly fits 
in FIXa active site.  Finalizing the AMRI complex will be a PN2-KPI inhibitor, which has 
previously been demonstrated to inactivate FIXa. 
2.1 Protease Nexin2 - Kunitz Protease Inhibitor (PN2-KPI) 
Anchored Kunitz-based inhibitors bound to lipid membranes have been successfully 
utilized for analysis of serine protease activity using Surface Plasmon Resonance (SPR).  
SPR allows for measurement in a real-time binding of two molecule companions without 
the need of labels by detecting the changes in refractive index (GE Healthcare, 
Technology Note 23: Label-free interaction analysis in real-time using surface plasmon 
resonance. (2007) BR-9004-63 28-9214-39 AA.).  The researchers generated a 
phosphatidylcholine (PC) lipid monolayer containing nickel chelating head groups and 
successfully attached 6-histidine-tagged bovine pancreatic trypsin inhibitor (BPTI).  Over 
the attached BPTI lipid layer, soluble proteases flowed over and were bound, 
establishing proof that a bound Kunitz inhibitor is capable of remaining functional after 
attachment.  However, these studies found that binding rates were drastically lower than 
in other studies using solution-phase testing (56,	58).  One explanation of this is the 
desired orientation of proteases on the membrane and the close position of the inhibitor 
on the membrane.  This negative steric interaction is the reasoning for wanting the 
Kunitz inhibitor attached at a set distance above the membrane and allowing more 
favorable binding to the protease domain. 
The Kunitz Protease Inhibitor domain of Protease Nexin 2 (PN2) was employed to 
bind to the active site of FIXa (56,	71).  The precursor form of this protein, PN2-Amyloid 
β Protein Precursor (AβPP) was found to have a role in the regulation of specific 
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proteases in extracellular environments; specifically, with plaque deposits of those 
affected with Alzheimer's disease and Down syndrome (72).  Schmaier et al. found that 
PN2-AβPP was 71-fold more effective in ability to inhibit FIXa than antithrombin III (70,	71).  Neuenschwander et al. experimentally determined that using just the inhibitor 
domain of PN2 (PN2-KPI) displayed an increased affinity for FIXa (58).  PN2-KPI is a 
more ideal inhibitor for height determination of the FIXa active site. 
2.2 LAGC anchor with Apyrase leader sequence 
Hydrophobic anchoring of a protein to a lipid membrane is not a novel idea, but an 
evolved mechanism.  In unicellular organisms many membrane proteins utilize the 
Lipobox motif to anchor to the phospholipid. Roughly 75% of all lipobox sequences 
consist of the amino acid sequence, LAGC.  The cleavage between the Glycine and 
Cysteine results in the formation of an N-terminal Cys.  The SH group on the new N-
terminal Cys is acted on by diacylglycerol transferase, creating the diacylglyceryl moiety.  
This moiety with Cys incorporated serves as the anchor to the phospholipid surface so 
that the attached protein does not diffuse away (75).  
Bhargava et al. identified a 23 amino acid leader sequence for virulent apyrase gene 
that is responsible for translocation of the protein from the cytosol to the periplasmic 
space in Gram-negative bacteria.  Identification was possible via cloning and expression 
of Shigella flexneri 2a apyrase gene in an E. coli plasmid (76).  Apyrase was directed to 
exit the cytosol and travel to the periplasmic space through translocase.  The leader 
sequence on the N-terminal end is recognized and transported to the periplasmic space.  
The clone was then sequenced against the wildtype for confirmation of the apyrase 
gene.    
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Kamalallannan et al. demonstrated an engineering process for converting a non-
lipoprotein into an anchored lipoprotein (75).  Using the Shigella apyrase leader 
sequence for transport, anchoring with LAGC sequence combined with normal protein 
sequence generated a viable lipid bound protein.  With the Cys serving as the anchor on 
the N-terminus end, it allowed for regular protein expression on the C-terminal end.  
2.3 Linkers= (EAAAK)11 (GGGGS) 
Linker construct has become an essential tool in the development of protein fusion.  
The ability to link proteins and not interfere with their reactivity is vital and achieved by 
taking into consideration flexibility and hydrophilicity (77,	78).  The sequence EAAAK, 
whose parent strand, initially described by Marqusee and Baldwin in 1987, is referred to 
as a rigid linker, forming alpha helices (78). This helix is stabilized by Glutamic acid and 
Lysine salt bridges and internal Hydrogen bonds (74,	77-79).  Arai et al. determined that 
it was possible to control the distance between two proteins by manipulating the 
repetition of the EAAAK motif (77,	80).  Amet et al. described the use of EAAAK linker 
sequence by varying the number of sequence repeats to optimize reactivity of an 
expressed protein (81).  
As the number of EAAAK motif repeats increases, so does the strength and 
tightness of the alpha helix structure (80).  Through FRET studies and high-resolution 
models, it also determined that the linkers connect diagonally and not longitudinally 
creating a vertical increase of 7.5 Å and not the interdomain distance of 10 Å, with 
(EAAAK)5 having a distance of 43.86 Å (74,	77,	80).  It was concluded that the rigid 
linkers provided a lesser degree of distance fluctuation between the N and C terminus.  
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Li et al. also confirmed through molecular dynamic simulation that EAAAK in helical form 
is in the lowest energy state, indicating conformational stability (74).   
The GGGGS sequence is a well-known flexible linker with many applications in 
protein engineering.  This flexible nature allows for the mobility of the inhibitor and the 
tethered EAAAK rigid sequence.  In the Li et al. 2015 study on molecular dynamics, it 
was found to have no energy change in the 29ns simulation and produced total energy 
fluctuation the entire time (74). This is indicative of a protein with no conformation 
stability.  The flexible linker also produced an increase in variable distances in the FRET 
analysis conducted (74,	80).  Incorporation of the flexible linker at the end of the rigid 
linker sequence supplies a lack of conformation, making it ideal to serve as the 
"intermediary" between the rigid linker and inhibitor.  This lack of conformity will provide 
the inhibitor with freedom of movement to fit within the catalytic head of FIX. 
  
	
Figure 6  Structure formations of EAAAK and GGGGS.  This demonstrates how the proposed 
protein structure will be rigidly lifted from the phospholipid membrane, while GGGGS provides 
the flexible conduit for proper insertion of the inhibitor 
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4 Specific Aims 	
The focus of this study is to generate a lipid Anchored Molecular Ruler with attached 
Inhibitor (AMRI) at a fixed height to quantify the optimum reactive height for FIXa.  The 
hypothesized reactive height is a distance between 50 to 100Å above the membrane.   
Specific Aim 1: Creation of an AMRI in an expression vector. 
Specific Aim 2: Purification of AMRI in an expression vector. 
Specific Aim 3: Sequencing of AMRI in an expression vector. 
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5 Methods 	
5.1 SnapGene 	
SnapGene® software (from GSL Biotech; available at snapgene.com) was used for 
vector mapping and design.  The PCR primers and oligonucleotides were designed with 
the program including the LAGC anchor region to attach to a phospholipid membrane; 
an EAAAK (EA3K) rigid linker serving as a molecular ruler; a PN2-KPI region serving as 
the FIXa inhibitor; the PCR primers needed to correct the orientation of the current p-
LAGC-EAK10 plasmid. 
5.2 Vector Preparation 
5.2.1 Description 	
pET11d plasmid was used for the cloning backbone.  The p-LAGC-EAK10 plasmid 
was a gift from a previous GA-PCOM thesis student.  This plasmid contained the 
Shigella apyrase leader sequence, anchor sequence LAGC, and the molecular ruler 
sequence of EAAAK repeated 10 times inserted between the NcoI and HindIII restriction 
sites. 
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5.2.3 Growth 	
Streak plates of DH5α Escherichia coli (E. coli) were made with LB agar (10 g/L 
tryptone, 5 g/L yeast extract, 10 g/L NaCl, 15 g/L Difco Granulated agar, pH 7.0) 
containing ampicillin with a concentration of 50 µg per ml (82) .  The plate was placed in 
37°C incubator overnight and removed after growth and placed in 4°C for storage.  
Individual isolated colonies were chosen and inoculated into 5 ml culture tubes, 
containing LB media.  Ampicillin ensures the selection of only E. coli containing any 
vector with the gene conferring Ampicillin resistance; inhibiting growth of E. coli lacking 
ampicillin resistance.  The culture tube was then placed in a 37°C incubator at 250 rpm 
overnight.  This growth was to ensure a good cloudy density of bacterial growth.  1 mL of 
the initial 5 mL culture was used to inoculate 250 mL and 500 mL LB media cultures. 
5.2.4 Transfection 	
Competent DH5α E.coli cells were used for transfections and were a gift from Dr. 
Frank Jenney.  The DH5α cells were taken from the -80°C freezer and placed to thaw on 
ice. The cells were then stirred with the tip of a pipet, before pipetting 70µl into a pre-
chilled 1.5 ml tube.  There as one tube per each individual reaction.  10 ng of plasmid 
DNA was placed into the 70 µl of competent cells and stirred with a pipet tip.  This 
mixture was then placed on ice to incubate for 30 minutes, followed by 30 seconds of 
incubation at 42°C to heat shock the cells.  The tubes were immediately transferred and 
chilled on ice for 2 minutes.  Next, 300 µl SOC (20 g/L tryptone, 5 g/L Yeast extract, 0.5 
g/L NaCl, 10 ml/L 250 mM KCl, 5 ml/L 2 M MgCl2, 20 ml/L 1M glucose, pH=7.0) 
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prewarmed to 37°C was added to the cell mixture and allowed to shake for 1 hour at 100 
RPM.  The cells were then plated 100µl and 200µl on LB plates, both with and without 
the 50 µg/mL ampicillin selection agent.  In these experiments, different molar ratios of 
the digested vector and insert were used to obtain optimum transfection efficiency.  
Experimental molar ratios of 1:3 and 1:6 vector to insert were used.  Controls included 
vector plus ligase only, and DH5α cells only.  Once plated the plates were allowed to dry 
before placing inverted at 37°C overnight.  Isolated colonies on the successful plates 
were then inoculated into an LB broth with ampicillin as described above.  
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5.2.5 DNA Miniprep 	
DNA Miniprep was performed to screen for the intended clone at various stages of 
the cloning process.  Quantum Prep® Plasmid Miniprep Kit (Bio-Rad Laboratories Inc., 
Hercules, California, Catalog #732-6100) was used in all Miniprep procedures.  During 
this process, centrifugation was performed at the maximum speed of 13,300 x g on a 
tabletop centrifuge. Using 1 to 2 ml of the growth culture the protocol was followed 
depending on the desired final concentration of pure plasmid.  The culture was placed in 
a microcentrifuge tube to pellet the cells and ran for 30 seconds. With the cells pelleted 
the supernatant was removed by pipetting.  Then another quick spin on a small desktop 
centrifuge was performed just to ensure removal of supernatant.  The pellet was 
resuspended using 200 μl of the Cell Resuspension Solution provided by vortexing and 
pipetting up and down.  Next 250 μl of the Cell Lysis Solution were added and mixed by 
gently inverting the capped tube about ten times.  The Cell Lysis Solution was followed 
by the addition of 250 μl Neutralization Solution then inverted 10 times for complete 
mixture.  A precipitate formed and was then placed back in the centrifuge for 5 minutes 
to collect the cell debris.  The plasmid DNA, located in the clear lysate, was transferred 
to a spin filter, and combined with 200 μl mixed Quantum Prep Matrix, with the filter 
placed in a 2 ml centrifuge tube.  The tube with the filter was centrifuged for 39 seconds.  
The spin filter was removed, and filtrate discarded, then put back in the centrifuge tube 
and washed twice with 500 μl of Wash Buffer.  The first wash was centrifuged for 39 
seconds and the second was for 2 minutes.  An additional spin was performed if a slight 
smell of ethanol persisted.  The filter was then placed in a 1.5 ml microcentrifuge tube 
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and eluted for 1 minute with 100 μl of prewarmed 70°C nuclease-free water.  The 
purified DNA was then either stored at -20°C or used immediately. 
5.2.6 DNA Midiprep 	
Quantum PrepTM Plasmid Midiprep Kit (Bio-Rad Laboratories Inc., Hercules, 
California, Catalog Number 732-6120) was used for collection of larger pure plasmid 
DNA amounts.  All centrifugation was in a swing bucket table-top centrifuge using 250 ml 
Oak Ridge tubes.   250 ml growth media was centrifuged at 5,000 × g for 10 minutes to 
pellet the cells. The tubes were then drained of supernatant and inverted on a paper 
towel to ensure removal of media.  The pellet was resuspended with 6 ml Cell 
Resuspension Solution and mixed by vortexing until all cells were back in solution. Next, 
6 ml of prewarmed 37° Cell Lysis Solution were added and mixed by rolling on the 
benchtop.  This mixture was allowed to sit for 3 minutes at room temperature before 
adding 10 ml Neutralization Solution and mixed by inverting 5 times. After 3 minutes a 
white flocculant formed.  This solution was then placed in a PureYieldTM Clearing 
Column and a new 50ml disposable Falcon plastic tube, then allowed to sit for an 
additional 2 minutes at room temperature before centrifuging at 2,500 × g for 10 
minutes.  Then filtered lysate was transferred into a PureYieldTM Binding Column and 
new 50ml disposable Falcon plastic tube to which 5.0 ml of Endotoxin Removal Wash 
Solution were added. This was centrifuged at 1,500 × g for 3 minutes, and the flow 
through was discarded.  Following the Endotoxin Wash were two washes of 20ml of 
Column Wash Solution, discarding the flow through each time.  At the completion of the 
second wash, the column tip was tapped dry on a paper towel and placed in a new 
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Falcon tube and spun for 15 minutes at 1,500 × g.  The column was then allowed to sit 
for 5 minutes or until no smell of ethanol remained.  Next, the column was placed in a 
new Falcon tube, and 600 μl of prewarmed 70°C nuclease-free water was allowed to sit 
on the column membrane to rehydrate. After 2 minutes the tube was centrifuged for 5 
minutes at 1,500 × g.  The filtrate was collected and placed in a 1.5 centrifuge tube. 
5.3 DNA Analysis 	
5.3.1 Thermo Nanodrop Spectrophotometer 	
The ThermoFisher Scientific Nanodrop Spectrophotometer, now referred to as 
NanoSpec, was started using the setting for double-stranded DNA and was calibrated 
using only 2 μL of nuclease-free water. Then 2 μL of DNA sample was added to the 
NanoSpec to determine concentration (ng/μL).  The NanoSpec made measurements by 
wavelength absorbance at 260 nm for Nucleic Acids and 280 nm for proteins.  This 
A260/A280 ratio reading was calculated to determine DNA purity; a ratio of close to 2.0 is 
considered pure for DNA, however anything above a 1.8 was considered acceptable for 
use. 
5.3.2 Agarose Gel Electrophoresis 	
A 1% agarose gel (10 mg/mL of Nuclease-free agar in 1X TAE Buffer (Tris-acetate-
EDTA, pH 8.3)) was separated using 0.1 µL/mL GelRed™ Nucleic Acid Gel Stain 
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(Phenix Research Products, Candler, North Carolina) in 1X TAE running buffer.  For 
tracking the progression of DNA in the agarose, 5 μL Quick-Load 2-Log DNA Ladder 
(New England BioLabs, Ipswich, Massachusetts, Catalog # N0550S) was employed for 
size analysis and each loaded sample had 5 μl of Gel Loading Dye, Purple (6X), no SDS 
(Catalog # B7025S) per 25 μl reaction volume.  The DNA and loading dye mixture were 
mixed well on Parafilm before being loaded into the desired well in the agarose gel.  
Once the desired amount of DNA was loaded into the agarose gel wells, including the 
ladder, the current was started at 100 Volts and ran for approximately 45 to 95 minutes 
depending on the tracking of the red band generated by the purple load dye. The red 
band tracks through the 1% agarose gel as a piece of DNA with approximate length of 
300 base pairs.  This was important for direction, speed of travel, and to determine time 
run time for proper separation of different sized bands.  This same method was 
employed for DNA band isolation for determining digested and undigested plasmid DNA.  
To determine the DNA amounts gel quantification was applied to either verify the 
concentration determined by the NanoSpec or used as a stand-alone result.   
5.3.3 Sequencing 	
Sequencing performed in this project was conducted by Retrogen Incorporated in 
San Diego, California. The primer used in sequencing was against the T7 tag vector 
sequence.  The data generated by Retrogen was then imported into the SnapGene® 
software for alignment analysis. 
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5.4 Resuspension of Lyophilized PN2 oligonucleotide 	
Lyophilized samples of the forward and reverse PN2 oligonucleotides were ordered 
from Integrated DNA Technologies.  When received the samples appeared translucent 
and were virtually undetectable to the naked eye.  The samples were first centrifuged at 
maximum speed for 1 minute before opening the tops of their centrifuge tubes.  Then 
concentrated stock for each were resuspended at a concentration of 100 µM and a 
working stock concentration of 10 µM; both made with TE Buffer (10mM Tris; 0.1 mM 
EDTA; pH 8.0).  The following oligonucleotides were generated by Integrated DNA 
Technologies, Inc. (Skokie, Illinois):    
5.5 Design of PN2 	
The forward and reverse oligonucleotides were ordered with the plan to anneal them 
together. Thus, the annealed double stranded product would constitute the sequence for 
to the PN2 inhibitor with overhangs matching the HindIII and EcoRI restriction sites. 
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5.5.1 PN2 forward 
Sequence - PN2 forward 20 nmole Ultramer® DNA Oligo, 186 Bases 
5- /5Phos/AAT TAA GCA GAA CCA CAA ACA GCC ATA CAG TAC TCC TCA 
GTG TCG AAG TTG TTT CTG TTA CCA CCA CAA CCA CCG TAG AAG AAT GGA 
GCA CAC TTA CCC TCA GTA ACG TCG AAG TAC CAT CTA GAA ATC ATA GCT 
CTA CAT GGA CCA GTC TCA GCT TGC TCA GAA CAA ACC TCT CTA ACA ACC 
TCC -3 
Properties: 
Tm (50 nM naCl): 70.7 °C 
GC Content: 45.2% 
Molecular Weight: 57016.9 
nmoles/OD260: 0.6 
ug/OD260: 31.6 
Ext. Coefficient: 1803400 L/(mole·cm) 
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5.5.2 PN2 reverse 
Sequence - Pn2 reverse 20 nmole Ultramer® DNA Oligo, 186 Bases 
5- /5Phos/AGC TGG AGG TTG TTA GAG AGG TTT GTT CTG AGC AAG CTG 
AGA CTG GTC CAT GTA GAG CTA TGA TTT CTA GAT GGT ACT TCG ACG TTA 
CTG AGG GTA AGT GTG CTC CAT TCT TCT ACG GTG GTT GTG GTG GTA ACA 
GAA ACA ACT TCG ACA CTG AGG AGT ACT GTA TGG CTG TTT GTG GTT CTG 
CTT -3 
Properties: 
Tm (50 nM naCl): 70.8 °C 
GC Content: 46.2% 
Molecular Weight: 57940.3 
nmoles/OD260: 0.6 
ug/OD260: 32.3 
Ext. Coefficient: 1793300 L/(mole·cm) 
Annealing of forward and reverse PN2-KPI primers results in following structure: 
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5.6 Restriction Digest 	
New England Biolabs restriction enzymes, XbaI (Catalog #R0145S), NcoI-HF 
(Catalog #R3193L), HindIII-HF (Catalog #R3104L), EcoRI-HF (Catalog #R3101L), and 
Alkaline Phosphatase, Calf Intestinal (CIP) (Catalog #M0290L), had incubation 
temperatures of 37°C in NEBuffer CutSmart buffer.  All restriction enzymes could be 
heat inactivated at temperatures of 80°C, except for Calf Intestinal Phosphatase (CIP).  
Therefore, all reactions were performed in a ThermoFisher Applied Biosystems™ 
Veriti™ 96-Well Thermal Cycler under controlled conditions.  The heat inactivation of 
XbaI was 65°C, but for the simplicity of programming 80°C was used.  The reaction 
conditions XbaI (Catalog #R0145S), NcoI-HF (Catalog #R3193L), HindIII-HF (Catalog 
#R3104L), EcoRI-HF (Catalog #R3101L) were as follows: 
Restriction Enzyme 20 units 
DNA Up to 1 µg 
10X NEBuffer CutSmart 5 µl (1X) 
Total Reaction Volume 50 µl 
Incubation Time 3 hours 
Incubation Temperature 37°C 
Heat Inactivation Time 20 minutes 
Heat Inactivation Temperature 80°C 
Once the first restriction digest was completed the DNA was purified by gel 
electrophoresis and extracted as described.  The next restriction was only heat 
inactivated before with the  Calf Intestinal Phosphatase (CIP) treatment 
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The CIP treatment was performed to remove the 5’-phosphate by the addition of 20 
units of CIP to the previously heat inactivated digest.  The ThermoFisher Applied 
Biosystems™ Veriti™ 96-Well Thermal Cycler was programmed to run for 1 hour at 
37°C to allow the phosphatase to cleave.  Afterwards, the temperature dropped in the 
ThermoFisher Applied Biosystems™ Veriti™ 96-Well Thermal Cycler to 4°C until 
removed.  After the CIP treatment, a Phenol-Chloroform-Isoamyl Extraction with Ethanol 
precipitation to stop the phosphatase was performed. 
5.7 Purification 	
5.7.1 Phenol-Chloroform-Isoamyl Extraction 	
To remove the restriction enzymes and ensure that the DNA is free of proteins and 
lipids it is essential to perform an extraction.  Once the extraction is performed the 
purified DNA is then able to be used in the next phase of the experiment.  The DNA 
mixture was mixed with one volume of phenol:chloroform:isoamyl alcohol in a ratio of 
25:24:1, respectively.  The solution was then vortexed thoroughly for approximately 20 to 
30 seconds, followed by centrifugation at room temperature for 2 minutes at 13,300 x g.  
Next, the upper aqueous layer was removed and transferred to a fresh tube, being 
careful to not get phenol during pipetting.  To ensure the removal of all phenol another 
wash was performed with equal volume of chloroform, then vortexed for approximately 
20 to 30 seconds, followed by centrifuging at room temperature for 2 minutes at 13,300 x 
g.  The upper aqueous layer was transferred to a fresh tube for ethanol precipitation.  
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5.7.2 Ethanol Precipitation 	
The microcentrifuge tube containing the DNA solution had 3M Sodium Acetate 
added at 1/10 volume, then vortexed to ensure mixture of salt with DNA.  Next, 2X 
volume ice-cold 100% Ethanol was added and vortexed to provide a complete mixture.  
The mixture was placed in -80°C for at least 1 hour but typically left overnight.  When the 
mixture was removed, the mixture was centrifuged at 13,300 x g for 20 minutes at 4°C.  
The supernatant was then decanted carefully to not disturb the pellet.  Next, the pellet 
was washed with 70% ice-cold ethanol and allowed to stand at room temperature for 5 
minutes.  The tube was then centrifuged again at 13,300 x g for 20 minutes at 4°C, and 
the supernatant was removed by pipetting.  The pellet was then air dried for 
approximately 20 to 30 minutes or until no trace smell of ethanol existed.  The dried 
pellet was then resuspended with 20-40 μL Nuclease-free water or 1X TE buffer via 
gently pipetting.  The resuspension was incubated at 37°C for 15 to 20 minutes to 
ensure resuspension. 
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5.8 Ligation 	
New England Biolabs T4 DNA Ligase (400,000 cohesive end units/ml; Catalog # 
M0202L) was used in all ligations.  The protocol was set up as follows:   
Vector DNA 1.000x10-5-2.000x10-5 nmol 
Insert DNA 3.000x10-5-5.000x10-5 nmol 
T4 DNA Ligase 400 Units 
T4 DNA 10X Ligase Buffer 2µl 
Nuclease-free water Up to 20 µl 
Total Reaction Volume 20µl 
 
Vector DNA to Insert DNA was set up at a 1:3 or 1:6 molar ratio.  This reaction was 
set up on ice and the T4 ligase added last.  The reaction was placed in the 
ThermoFisher Applied Biosystems™ Veriti™ 96-Well Thermal Cycler for 14 hours at 
16°C.  The reaction was stored in the 4°C refrigerator or on ice until used in the 
transfection.  
5.9 Polymerase Chain Reaction 	
The following PCR primers generated by Integrated DNA Technologies, Inc. (Skokie, 
Illinois) were used for sub-cloning the original insert with the restriction sites in a different 
reading frame orientation. 
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5.9.1 Primer #1: HindIII replacing NcoI-NT 
The 34 Bases of Sequence - HindIII replacing NcoI-NT were 5’- ATA CAA AGC 
TTC ATG GGC TAC CAC CAC CAC CTT T -3’.  Properties of the designed primer 
sequence were: 
Tm (50 nM NaCl): 65.2 °C 
GC Content: 47.1% 
Molecular Weight: 10290.7 
nmoles/OD260: 3.1 
ug/OD260: 32.4 
Ext. Coefficient: 317900 L/(mole·cm) 
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5.9.2 Primer #2: NcoI Replacing HindIII-OT 
The 42 bases of Sequence - NcoI Replacing HindIII-OT were 5’- ACA CCA TGG 
AGC TTA TGA AAA CCA AAA ACT TTC TTC TTT TTT -3’.  Properties of the 
designed primer were: 
Tm (50 nM NaCl): 61.9 °C 
GC Content: 31% 
Molecular Weight: 12805.4 
nmoles/OD260: 2.5 
ug/OD260: 31.9 
Ext. Coefficient: 400800 L/(mole·cm) 
 
  
The oligonucleotides were resuspended in TE buffer (10mM Tris; 0.1 mM EDTA; pH 
8.0) with a 100 μM concentrated resuspension and a 10 μM working stock working stock 
concentration  
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The Polymerase Chain Reaction mixture was set up as follows using the Q5® HF 
polymerase kit (New England Biolabs; Catalog # M0492S). 
 Final 
Concentration 
Q5 HF Master Mix 2X 1X 
10 µM  of Primer #1: HindIII replace NcoI-NT 0.5 µM 
10 µM of Primer #2: NcoI replace HindIII-OT 0.5 µM 
PLE10 Template DNA 1 pg 
Nuclease-Free Water Up to 50 µL 
Total Volume 50 µL 
 
This mixture was placed in a PCR reaction tube.  The ThermoFisher Applied 
Biosystems™ Veriti™ 96-Well Thermal Cycler ran using the program NPB Q5 HF 
method 2, which was programmed as follows:  
Step Temperature (°C) Time (seconds) 
Denaturation 98 30 
35 cycles 98 10 
 72 60 
Final Extension 72 120 
Hold 4 ∞ 
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Once the PCR was completed the PCR tubes were pooled and placed in 4℃ 
refrigerator.  Analysis of the PCR product was performed with the NanoSpec to 
determine DNA concentration of the PCR products.  
5.10 DNA extraction from Agarose Gels 	
QIAEX II® Gel Extraction Kit (Qiagen; Hilden, Germany; Catalog # 20021) was used 
to harvest DNA from agarose gels.  The manufacturer's protocol was followed but 
modified to fit specific requirements. 
DNA product was loaded into the well of a 1% TAE agarose gel that was contained 
in a Gel Electrophoresis Chamber and electrophoresed at 100 volts for roughly 60 
minutes.  The 1% TAE agarose gel, containing electrophoresed DNA product, was 
imaged with an UV gel imager.  The individual bands were excised while under UV light 
to determine precise location using a sharp scalpel blade.  If DNA banding patterns were 
not clearly distinct to separate based on size compared to the NEB Quick-Load 2-Log 
DNA Ladder and other DNA products in same lane, then the gel was placed back into 
the Gel Electrophoresis Chamber in 10-minute increments until optimal separation was 
obtained.  To maximize the recovery all agarose lacking DNA was removed from the 
excised band, so the weight of agarose was approximately 250 mg.  The agarose 
containing DNA was placed in an empty, pre-weighed 2 ml microcentrifuge tube, and 
weighed to determine mass.  Next, 2 volumes of Buffer QX1, 2 volumes of nuclease-free 
H2O, and 30 µl of QIAEX II solution were added to 2 ml microcentrifuge tube.  The 
QIAEX II solution was vortexed exceptionally well to ensure proper mixture before 
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adding to the buffer containing the agarose.  After addition of QIAEX II, the solution was 
incubated at 65°C for 12 minutes, and vortexed every 2 minutes.  Intermittent vortexing 
allowed proper binding of QIAEX II to the DNA.  Next, the solution was centrifuged for 30 
seconds at maximum speed, and the supernatant was removed with a pipet.  A pellet 
wash was performed with 500 µl of Buffer QX1 and vortexed to resuspend the pellet.  
The supernatant was pipetted and discarded after a 30-second centrifuge.  Next, the 
pellet was washed twice with 500 µl of Buffer PE.  For each wash, the pellet was 
vortexed to resuspend in solution, then centrifuged to pellet the QIAEX II beads and 
supernatant was removed.  After final wash was completed, the pellet was air dried for 
30 minutes or until the pellet was white.  With a dry white pellet, the DNA was eluted with 
40 µl of nuclease-free H2O, vortexed the pellet to resuspend, and incubated at 70°C for 
15 minutes.  The resuspended pellet was stirred with a pipet tip and incubated an 
additional 5 minutes.  The DNA yield was increased by a final maximum speed 
centrifugation that lasted a minimum of 30 seconds, but less than 45 seconds.  This last 
step eluted additional DNA into the nuclease-free water.  Next the nuclease-free water 
that contained eluted DNA was pipetted into a new centrifuge tube.    
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6 Results 	
6.1 Dissection of pET11D  	
E.coli DH5α was chosen as a 
plasmid maintenance host of pET11D. 
Figure 7 demonstrates a vector map of the 
pET11d plasmid isolated from the bacterial 
cell.  The plasmid contains multiple 
restriction sites that were selected based 
on location and orientation to the ribosome 
binding site (RBS) and the open reading 
frame (ORF).  
The gene encoding LAGC-
(EAAAK)11,  to be named AMR, was 
previously cloned into the pET11d plasmid 
and was gifted from a former Georgia 
Campus – Philadelphia College of 
Osteopathic Medicine Thesis Student, Robin Conley (83). The Apyrase leader sequence 
directs translocation of the LAGC sequence from the cytosol to the periplasmic space of 
the E.coli and is then cleaved by the cellular machinery.  The LAGC, a portion of the 
lipobox protein, serves as a signal sequence that is cleaved, then modified with an N-
acetyl moiety.  Each EAAAK motif forms a rigid alpha helical structure which will extend 
	
Figure	7	pET-11d Vector Map with a length of 6,674 base 
pairs. The restriction sites used are identified with names 
and locations on the vector. Also noted is the Open 
Reading Frame direction and location of the Ampicillin 
Resistance Gene. 
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from the N-acyl-S-diacylglycerylcysteine lipid anchor moiety.  To achieve the desired 
distance between the inhibitor moiety and the phospholipid anchor, the EAAAK motif 
was repeated a total of eleven times.  Encoded at the terminus of the EAAAK region is a 
GGGGS flexible linker sequence.  The flexible nature of GGGGS allows for the mobility 
of the inhibitor, instead of being directly tethered to the rigid EAAAK sequence 
6.2 PCR Reorientation and Purification of AMR 	
 
Figure 8  pET-11d Vector Map with the LAGC-EAAAK sequence inherited from a previous student.. The 
restriction sites used are identified with names and locations on the vector. Also noted is the Open Reading 
Frame direction and location of the Ampicillin Resistance Gene. 
The gifted plasmid, p-LAGC-EAK11, contained the Shigella apyrase leader 
sequence, anchor sequence LAGC, repeated ruler sequence EAAAK and flexible linker 
sequence GGGGS inserted between restriction sites NcoI and HindIII (see Figure 8).  
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Employing the p-LAGC-EAK11 plasmid as the cloning backbone for the PN2 inhibitor, in-
depth analysis determined the reading frame directionality was incorrect.  Correct 
placement of AMR sequence is necessary for not only protein expression but for the 
addition of the PN2-KPI inhibitor.   
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Figure 9  Master Plan Overall View. Correction of pET-11d  Vector with the LAGC-EAAAK (AMR) sequence 
inherited from a previous student. Redesign of the PN2-KPI and insertion into the vector to produce the final 
product, AMRI. The restriction sites used  are identified with names and locations on the vector. Also noted 
is the Open Reading Frame direction and location of the Ampicillin Resistance Gene. 
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A master plan (see Figure 9) was developed to use PCR to re-engineer the 
restriction sites and correct the AMR reading frame orientation by subcloning out the 
previous bits and swapping their orientation before adding the 
PN2-KPI sequence.  The new reverse strand, named ‘HindIII 
replacing NcoI-NT’,  and the new forward strand, named ‘NcoI 
replacing HindIII-OT’ were used to re-engineer the orientation 
of the strand.  Following the PCR, the entire AMR sequence 
underwent a double digest with HindIII and NcoI.  Upon 
completion of the restriction digest, a Phenol/Chloroform 
extraction was performed to purify the AMR product.  Gel 
electrophoresis (See Figure 10) and was performed on the 
AMR product to ensure size of the product.  Once confirmed 
that the product was of desired size the process was repeated 
on a larger scale and gel analysis had a concentration of 725 
ng Restricted Flipped Insert used in the gel analysis (see 
Figure 10).  The NanoSpec reading on the total collected volume was 6640 ng total of 
AMR insert from the PCR reaction. 
6.3 Purification of Restricted pET11d Plasmid 	
Generation of new E.coli DH5α containing the pET11d plasmid was performed to 
have ample stock for the pET11d-AMR ligation reaction.  For the generation of sticky 
ends, the pET11d vector was restricted with NcoI in the thermocycler for 3 hours at 
37°C, followed by heat inactivation at 80°C for 20 minutes, and held at 4°C until removal 
10	
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Figure	2	
Confirmation 
of AMR PCR 
product. The 
expected 
band size is  
356 base 
Figure	10	
Confirmation of AMR 
PCR product. The 
expected band size is  
356 base pairs. 
KB	
3	
1	
0.5	
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from thermocycler.  A 1% agarose gel containing Phenix Red was the standard for all gel 
purifications with the bands excised under UV light, and plasmid DNA harvested via 
QIAEX-II gel extraction kit (see Figure 11). 
When using the gel extraction kit, following the 
manufacturer's protocol except for the heat 
recommendation, a heat setting of 65°C to 70°C was 
found to be optimal for extraction of DNA from the 
QIAEX-II beads.  The NanoSpec then quantified the 
NcoI_pET11d plasmid concentrations to ensure both 
quantity and quality. 
pET11d_NcoI plasmid was then restricted with 
HindIII for 2 hours in the thermocycler, heat inactivated 
at 80°, and held at 4°C.  The pET11d_NcoI_HindIII 
plasmid was CIP treated at 37°C in the thermocycler for 
1 hour.  Purified pET11d_NcoI_HindIII_CIP was 
obtained by two phenol/chloroform extraction and single 
ethanol precipitation.  Quantification was performed 
using the NanoSpec reading to generate the total 180.4 
ng of DNA.  
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Figure	11	pET-11d Restriction. In 
lanes 4 and 5 the plasmid has been 
digested with HindIII, lanes 7 and 8 
have been digested with NcoI.  
Based on the band size an 
estimated concentration of 600 ng 
per lane of DNA. 
KB	
10	
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Lane	 5	 7	 8	
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6.4 Insertion and Transformation of AMR Insert 	
The importance of molar ratios comes into 
account for ligation reactions to occur between 
pET11d_NcoI_HindIII_CIP and AMR.  The 
ligation was performed overnight at a 1:3 vector 
to insert ratio at 16°C in the thermocycler.  At the 
completion of ligation, a transformation was 
setup using competent E.coli DH5α cells, a gift 
from a former GA-PCOM pharmacy student, 
Betty Ma.  To the competent cells, 10 ng of 
plasmid was pipetted into them, heat 
shocked at 42°C for 30 seconds, thus 
allowing the DNA to be transformed 
into the E. coli cells.  The cell cultures 
were grown overnight at 37°C and 
colonies were observed (See Figure 
12).  Selections were made from the 
chosen colonies and inoculated into 5 
ml LB broth with 50 µg/mL ampicillin 
and grown overnight Midiprep was 
performed the following day.  To 
	
	
	
	
	
	
	
Figure	12	Transformation of p_AMR into E.coli 
DH5α. The colonies were identified and circled 
so that origin could be traced in detail before 
Miniprep  was performed to send the plasmid 
DNA for analysis. 
KB	
Figure	13	Gel Electrophoresis Image of  double 
digested Transformation Product. The Miniprep 
harvested plasmid was double digested with NcoI and 
HindIII as confirmation before sending samples for 
sequencing analysis. The double digest plasmid has 
an expected size of 5,348 base pairs. Quick-Load 2-
Log DNA Ladder (New England BioLabs, Ipswich, 
Massachusetts, Catalog # N0550S) was employed for 
size analysis.	
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confirm the ligation and transformation a success a double digest with NcoI and HindIII 
on the harvested P_AMR plasmid was performed  with the restricted plasmid being 
5,348 bp and the fragment 251 bp (See Figure 13).  The harvested plasmids were sent 
to Retrogen for sequencing from the T7 (See Appendix A).  A positive colony, named 
P1CB1, was chosen as the Gold Stock colony for all future P_AMR plasmids due to its 
complete sequence.  
6.5 Annealing and Purification of PN2-KPI 
The PN2-KPI inhibitor was annealed by mixing in equal concentrations of oligo and 
heating to 94°C for 2 minutes, followed by slowly cooling to room temperature.  A small 
amount was then used to run for analysis and quantification of product. 
6.6 Harvest of P_AMR for use in Transformation 
P_AMR was then harvested from E.coli to be used for a series of restrictions 
before the ligation of the PN2.  The first restriction was with EcoRI as previously 
performed with HindIII, followed by gel purification, and QIAEX-II gel extraction.  
NanoSpec quantification and gel verification was used to ensure full linearization before 
proceeding to the restriction with HindIII.  Next, was a restriction of P_AMR_EcoRI with 
HindIII for 2 hours was performed in the thermocycler at 37°C, followed by heat 
inactivation at 80°C for 20 minutes.  The p_AMR_EcoRI_HindIII was then treated with 
CIP for 1 hour at 37°C.  To purify p_AMR_EcoRI_HindIII_CIP a 
phenol/chloroform/isoamyl extraction followed by ethanol precipitation, to ensure purity 
of the restricted DNA.  A quantification gel was used to determine the concentration of 
plasmid DNA after completion of purification. 
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6.7 Ligation and Transformation of p-AMR with PN2-KPI 	
A ligation reaction was set up between 
p_AMR_EcoRI_HindIII_CIP and PN2 insert at a 
molar ratio of 1:3 and 1:6. This reaction was placed 
in the thermocycler overnight at 16°C 
and used in a transformation into 
competent E.coli DH5α cells.  The 
chosen colonies (See Figure 14) were 
grown in 5 ml LB broth with 5 µg/mL 
ampicillin overnight, and a miniprep 
was used to harvest the plasmid DNA.  
To ensure the confirmation of the P_AMRI product, a restriction with XbaI resulted in the 
expected ejection of a 356 base pair fragment (See Figure 15).  After restriction 
	
	
	
	
	
	
	Figure	14		Image of Transformation colony selection of p_AMRI plasmid in 
E.coli DH5α. Isolated colonies were 
selected for inoculation to grow culture for 
sequence confirmation.	
Figure	15	Gel Confirmation of desired p_AMRI product. 
The plasmid was digested with XbaI. On the engineered 
p_AMRI XbaI has 2 different restriction sites in the cloned 
sequence, which ejected a fragment of 356 base pairs in 
length. Quick-Load 2-Log DNA Ladder (New England 
BioLabs, Ipswich, Massachusetts, Catalog # N0550S) 
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confirmation, the p_AMRI plasmid was sent to Retrogen for sequencing analysis (See 
Appendix B). 
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7 Discussion 	
The goal of this study was 
to design and generate a lipid 
Anchored Molecular Ruler with 
attached Inhibitor (AMRI) at a 
fixed height to quantify the 
optimum reactive height for 
FIXa (see Figure 16).  Having a 
hypothesized reactive height is 
between 50 to 100Å above the 
membrane it is important to 
create AMRI to fluid data and 
understanding of Serine 
Proteases, specifically for this 
study FIXa. This was carried out by creation, purification, and sequencing of an AMRI in 
an expression vector. 
Previous studies have demonstrated the use of a variable length peptide linker and a 
membrane bound inhibitor.  The understandings of previous FRET studies delivered 
great insight into a topographical orientation of the enzymes.  Using the FRET data 
allowed for height estimation of FIXa on a phospholipid surface, but it could not 
necessarily correlate with the optimal reactive height, nor elasticity of the active site of 
the enzyme when exhibiting maximum pro-coagulant activity.  This study focused on the 
Figure	16.	Hypothesized	Action	of	AMRI	interaction	with	FIXa	on		
a	phospholipid	surface.	Here	it	can	be	seen	how	the	AMRI	(figure	on	
left)	gets	the	right	height	and	the	flexible	linker	allows	the	inhibitor	
to	fit	in	the	reactive	site	of	FIXa	(structure	on	the	left)	 
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generation of a lipid-tethered inhibitor for use as a molecular ruler of FIXa through a 
successful engineering and multi-step cloning process. 
The p-LAGC-EAK10 plasmid underwent a restriction digest with Restriction 
endonucleases, HindIII and NcoI, to produce a DNA fragment containing the LAGC and 
(EAAAK)11 coding sequences.  Using the molecular biology program, SnapGene, PCR 
primers were designed to mutagenize the ends, inserting HindIII and NcoI sites opposite 
to their original design.  This “flipped” the sequence and inserted it into the correct 
reading frame with the Tag7 site, coding for methionine.   
Standard cloning techniques were employed to sub-clone the fragment into an empty 
Pet11d vector, harvested from E. coli DH5α. PN2-KPI oligonucleotides were designed 
on SnapGene and generated by Integrated DNA Technologies.  The PN2-KPI 
oligonucleotides were ordered in forward and reverse reading frames and annealed to 
create overhangs for alignment with their EcoRI and HindIII restriction sites.  For 
conformation of correct annealing the product was purified using gel electrophoresis; the 
bands excised were roughly 187 base pairs size.  
A digest of EcoRI and HindIII produced the sticky ends for insertion and ligation of 
annealed oligonucleotides encoding the sequence for PN2-KPI, into the constructed 
AMR plasmid.  The DNA was purified via Gel Electrophoresis and excising the band with 
a product size of 5754 base pairs.  The DNA was for sequencing starting at the Tag 7 
promoter to ensure that the final gene product is correct. 
The sequencing data (see Appendix B) demonstrate the success of generating a 
constructed AMRI sequence in a multi-step molecular cloning process.  Successful 
		
	
56	
insertion of 11 EA3K repeats will result in the PN2-KPI inhibitor having a raised height of 
roughly 83 Å above the membrane surface.  Ideally the height of 83 Å will prove ideal for 
inhibition of FIXa as crystal structures and previous FRET data have indicated that 
active site is between 61 – 89 Å (59,	60,	68). 
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8 Future Studies 
8.1 Protein expression and purification of AMRI 
8.1.1 Expression of LAGC-(EAAAK)11-PN2 (AMRI) 
 The construction of LAGC-(EAAAK)11-PN2 in DH5ɑ vector described in Specific 
Aim 1 would be expressed in E. coli BL21(DE3).  Carbenicillin would be used, replacing 
Ampicillin, since it would confer more stability with β-lactamases and resistance to 
producing satellite colonies in this expression step (82).  The plasmid would confirm 
correct coding sequence and correct reading frame orientation if E. coli BL21(DE3) 
produces colonies.  The cells would then be lysed, as expressed proteins would be 
anchored in E. coli periplasmic space, with a zwitterionic detergent and would remain in 
detergent.  Using the detergent would provide a suitable environment for the protein, 
since typically its lipid bound. 
8.1.2 Affinity Column Purification of LAGC-(EAAAK)11-PN2 (AMRI) 
Crude Cell Lysate 	
Purification of LAGC-(EAAAK)11-PN2 Crude Cell Lysate would be performed by 
Affinity Column Purification in 20 mM Tris-HCl, pH 7.5, 100 mM NaCl.  The Affinity 
column would be generated using Affi-Gel generating an amide bond to Trypsin.  The 
desired amount of Affi-Gel would be transferred into a funnel to separate and drain the 
supernatant.  The gel would then be washed three times with gel bed volumes of cold 10 
mM Sodium Acetate, pH 4.5.  Gel is transferred to a flask and the cold Trypsin solution 
is added at 0.5 ml per ml of gel, followed by one hour of gentle agitation at room 
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temperature.  Once completed the gel with trypsin would be transferred to a column and 
washed with water until column runs clear at O.D.280.  The column was chosen since 
Trypsin would bind with PN2-KPI attached at the end of the folded protein.  The column 
would be developed using an Equilibration Buffer of 20 mM Tris-HCl, pH 7.5, 100 mM 
NaCl, 0.1% Triton-X100 with a flow rate of approximately 1 mL per 2.5 minute.  The cell 
lysate would then be loaded at a rate of approximately 1 mL per 2.5 minute.  The cell 
lysate would then be eluted with 10 mM HCl, 500 mM KCl, 0.1% Triton-X100, pH 2 at a 
rate of 1 ml/min and fractions collected.  Elutions would then be neutralized by adding 20 
µl of 1M Tris-HCl, pH 7.5, as collected.  Elution fractions would then be analyzed at A280 
and relevant fractions would be pooled.  The column would be stored at 4℃ and in the 
starting buffer that contains 0.2% Sodium Azide (Unpublished protocol K. Baker). 
8.1.3 Re-lipidation of LAGC-(EAAAK)11-PN2 (AMRI) 	
For proper expression of AMRI, re-lipidation must occur on a phospholipid surface 
such as a liposome, this protocol has been adapted from Smith and Morrissey 2004 (84).  These liposomes would form as the detergent is removed from, creating a layer for 
AMRI to effectively sit along with FIXa.  Using the A280 readings for estimated protein 
concentration it would place in a ratio of 300 nM protein with 2.6 µM Phosphatidylcholine 
(PC) lipid.  The mixture would then be dried under Argon gas followed by continued 
drying under a vacuum.  The protein solution still in the elution buffer would be added to 
solubilize the lipids.  Detergent would be removed by adding 50 mg wet SM-2 bio beads 
to pool the lipid vesicles.  As the liposomes are forming, detergent is being removed, and 
the protein should re-lipidate into the liposome.  After two separate 1.5-hour rocking 
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events the liquid around the beads would be collected; with an additional 350 mg wet 
SM-2 bio beads added after first rocking.  
8.1.4 Gel Filtration Chromatography 	
Gel Filtration Chromatography would be employed using a 16 ml sepharose CL 2B 
300 column at room temperature.  The column would be equilibrated in a High Salt TBS, 
composed of 50 mM Tris-HCl, pH 7.5, 0.5 M NaCl with a running flow of 1 ml/min.  The 
replipidated protein samples would then be added to the column and allowed to settle in 
column matrix.  The High Salt TBS would then flow over the column at a rate of 1 ml/min 
and collecting fractions.  The fraction turbidity would be analyzed at A600 to determine a 
lipid elution profile and proteins would be measured at A280.  Then proteins would be 
analyzed on 15% SDS-PAGE gels, followed by Silver staining using the Morrissey 1981 
protocol (85).  This step would confirm the proteins are fixating to the lipid membrane 
and not generating protein null liposomes.  Proteins that are not bound to the liposome 
would elute early as they are small, and the lipids would elute in later fractions.  If the 
proteins bind with the lipid they would elute in the same fractions. 
8.1.5 Anticipated Results 	
I anticipate the engineering of the protein was correct and would produce a valid 
product.  Expression of the protein should be accomplished because the DNA sequence 
is in the correct reading frame inducible under the IPTG.  Isolation of the protein would 
be possible as well because of Trypsin and its affinity for binding.  
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8.1.6 Potential Problems and Alternative Strategies 	
Potential problems may arise in the extraction method with the detergent.  The 
detergent is essential in lysing the cells and providing soluble protein environment.  
Adjustments would be made at each step and evaluated, since this protocol was 
adapted from the purification of BPTI.  The previous protocol also lacked the larger rigid 
and flexible linker regions, which could affect how the inhibitor folds and behaves. 
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8.2 Determine ability of AMRI to inhibit FIXa 
8.2.1 Protocol 
To study reactive height of FIX, AMRI was incorporated into a liposome as described 
in specific Aim 2.  The liposomes would be constructed of 2 anionic phospholipids, 
phosphatidylserine, and phosphatidylcholine (PS and PC).  Their concentrations would 
be at 10% PS and 90% PC and should be able to promote optimal binding.  It has been 
demonstrated with their ability to bind Vitamin K-dependent clotting factors, which 
contain the N-terminal g-carboxyglutamic acid (Gla) domain (9,	86).  Once the liposome 
bound with AMRI is dried to a 96- well plate activated FIXa would be added.   FIXa has 
been previously activated by Russell’s Viper Venom and stored frozen until needed.  
Chromogenic substrate would be added and monitored at 405 nm to determine the 
amount of active enzyme that remain unbound by the inhibitor, modified from 
Neuenschwander et al. 2006 and Yu et al. 2014 (56,	87).  Rates would be plotted 
against inhibitor concentration to determine the Ki for AMRI. 
8.2.2 Anticipated Results 
I anticipate that AMRI would inhibit FIXa at the height hypothesized of using the 
(EAAAK)11 insert between the LAGC anchor and PN2-KPI.  
8.2.3 Potential Problems and Alternative Strategies 
A potential problem is the sequence of repeats may alter the binding ability of KPI to 
block the catalytic triad, therefore, to test this ability a mixture of inhibitor and substrate 
could be placed in solution.  If no reaction or weak reaction, this would be conclusive 
that AMRI is ineffective in a FIXa topography study.  It is also possible the inhibitor could 
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be raised to an ineffective height; if weak inhibition then alternative repeats of EAAAK 
could be used to determine the optimal height of FIX.  This would require multiple 
cloning experiments to adjust the EAAAK sequence repeats.  Also, an issue that may 
been encountered is either FIX or inhibitor does not anchor to the phospholipid for 
correct positioning.  If this is the case, then alternative concentration ratios of PS:PC 
could be used to see if a different concentration as a greater anchoring affect. 
  
		
	
63	
9 Clinical Significance 	
An abnormal blood clot forms in the blood vessel, called a thrombus.  This thrombus 
is the result of a clinical abnormality causing activation of the clotting cascade.  If the 
resulting thrombus moves in the vasculature, it is termed an embolus.  An embolus 
becomes dangerous as it travels and lodges in the narrowing of the vessel, restricting or 
terminating blood flow. 
Current medical treatment for a patient receiving a stent or angioplasty involves 
multiple preparation steps to ensure the patient does not develop an embolus.  The 
current medical intervention relies heavily on drugs that interfere with the clotting 
cascade.  Patients going in for stent placement are given a Ca2+ channel antagonist and 
injections of heparin during the procedure.  Once the procedure is completed the use of 
heparin and coumarin (i.e. Warfarin) are continued for 72 hours.  Following the 72 hours 
treatment with the coumarin is done for an indefinite amount of time, depending on the 
patients clotting times (88) . 
The hope of this study of pro-coagulant enzyme/membrane topography is to bridge 
the knowledge gap by studying the distances of fully pro-coagulant enzyme complexes.  
The information from this membrane-bound activity study could lead to the generation of 
inhibitors with an increased specificity.  Not only targeting enzyme reactivity but one 
directed to specific membrane topography of each enzyme.  Therefore, the results of a 
study with AMRI could greatly impact clinical therapies aimed at coagulation reaction 
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inhibition.  Most importantly of the therapies impacted the most would be treatment of 
thrombosis, surgical procedures, and the implantation of medical devices (i.e. stents) 
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10 Appendices 
10.1  Appendix A. SEQUENCE DATA IMAGES OF AMR 
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10.2  Appendix B. SEQUENCE DATA IMAGES OF AMRI 
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